JAZZ - ジャズ・ファ―マシュ―ティカルズ （Jazz Pharmaceuticals plc） ジャズ・ファ―マシュ―ティカルズJAZZのチャート
JAZZの企業情報
| symbol | JAZZ |
|---|---|
| 会社名 | Jazz Pharmaceuticals Plc （ジャズ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 ジャズ・ファーマシューティカル（Jazz Pharmaceuticals plc）（旧名：アズール・ファーマ（Azur Pharma Public Limited Company））は専門のバイオ医薬品会社。同社の市販製品は米国食品医薬品局（FDA）の認可を受けたナルコレプシー患者における脱力発作と日中の過度の眠気向けの治療薬である「Xyrem」（ナトリウムオキシベート経口液剤）、治療抵抗性統合失調症の治療に適応されるクロザピン口腔内崩壊錠である精神医学薬品のFazaClo（クロザピンUSP）LDとFazaClo HD、強迫性障害の治療のために市販される「Luvox CR」（フルボキサミンマレイン酸塩）、及び難治性の重度慢性疼痛の治療に適応される非オピオイド性髄腔内鎮痛剤である「Prialt」（ジコノチド髄腔内注射剤）を含む。平成24年6月、同社はEUSA Pharmaを買収した。平成24年10月、同社はMedaに女性健康事業を売却した。同社の市販製品は「Elestrin」（エストラジオールゲル）、「Gastrocrom」（クロモグリク酸ナトリウム、USP）、「Natelle One」（出産前のビタミン剤）及び「AVC Cream」を含む。 ジャズ・ファ―マシュ―ティカルズは、アイルランドのバイオ医薬品企業。医療ニ―ズに対応した製品の開発、商業化を手掛ける。ナルコレプシ―、血液学/腫瘍学、疼痛、精神医学の分野で承認済み製品を提供。おもな製品はナルコレプシ―治療薬のXyrem、急性リンパ芽球性白血病の治療薬Erwinazeなど。 Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases - often with limited or no options. Jazz Pharmaceuticals plc has a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. The company's focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic and solid tumors. They actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. |
| 本社所在地 | Fourth Floor Waterloo Exchange Waterloo Road Dublin 4 IRL |
| 代表者氏名 | Bruce C. Cozadd ブルース・C・コザッド |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +353 1-634-7800 |
| 設立年月日 | 37681 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2007年 |
| 従業員数 | 1210人 |
| url | www.jazzpharmaceuticals.com |
| nasdaq_url | https://www.nasdaq.com/symbol/jazz |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 734.07800 |
| 終値（lastsale） | 162.02 |
| 時価総額（marketcap） | 9787490158.96 |
| 時価総額 | 時価総額（百万ドル） 9423.223 |
| 売上高 | 売上高（百万ドル） 1793.346 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 10199.843 |
| 当期純利益 | 当期純利益（百万ドル） 278.94500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Jazz Pharmaceuticals PLC revenues increased 23% to $945.1M. Net income decreased 28% to $138.3M. Revenues reflect Royalties and contract revenues increase of 15% to $8.2M. Net income was offset by Selling general and administrative - Ba increase of 39% to $327.8M (expense) Intangible asset amortization increase from $51.9M to $108M (expense). |
JAZZのテクニカル分析
JAZZのニュース
Where Jazz Pharmaceuticals Stands With Analysts 2022/08/04 21:13:06 Business Insider Markets
Within the last quarter, Jazz Pharmaceuticals (NASDAQ: JAZZ ) has observed the following analyst ratings:…
Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q2 2022 Results - Earnings Call Transcript 2022/08/03 22:53:02 Seeking Alpha
Jazz Pharmaceuticals plc (NASDAQ:NASDAQ:JAZZ) Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Andrea Flynn - Vice President & Head-Investor Relations…
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance 2022/08/03 20:10:00 Finanz Nachrichten
DUBLIN, Aug. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2022, affirmed 2022 financial guidance1 and provided busine…
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance 2022/08/03 20:05:00 PR Newswire Media
DUBLIN, Aug. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2022, affirmed 2022 financial guidance1 and provided business updates. "We''ve had a highly productive second quarter across commercial, R&D and…
Jazz Pharmaceuticals Q2 2022 Earnings Preview (NASDAQ:JAZZ) 2022/08/02 21:35:38 Seeking Alpha
Jazz Pharmaceuticals (JAZZ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close.The consensus EPS Estimate is $4.19 (+7.4% Y/Y) and the…
New filing by JAZZ PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE 2022/07/06 20:45:10 The FEC
The JAZZ PHARMACEUTICALS, INC. POLITICAL ACTION COMMITTEE successfully filed their F3XA JUNE MONTHLY with the coverage period of 05/01/2022 to 05/31/2022 and a confirmation ID of FEC-1607047 *********CommitteeId: C00721811 | FilingId: 1607047 | FormType: F3XA | CoverageFrom: 05/01/2022 | CoverageThrough: 05/31/2022 | ReportType: JUNE MONTHLY*********
What SVB Says On Axsome''s Strategy Review On Sunosi For Sleeping Disorder 2022/06/29 19:22:57 Benzinga
Axsome Therapeutics Inc (NASDAQ: AXSM ) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA). SVB Leerink says its view on Sunosi has not changed. Jazz Pharmaceuticals Plc (NASDAQ: JAZZ ) struggled to differentiate Sunosi in a generic market, and SVB remains skeptical that Axsome will be able to do much better. Related: Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its … Full story available on Benzinga.com
IBD 50 Stocks To Watch: This Pharma Stock Rides Health Care Wave 2022/06/29 19:11:15 Investor''s Business Daily
Jazz Pharmaceuticals stands out in the IBD 50 as it rides the wave of the health care sector on concerns of a looming recession.
Jazz Pharma''s Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity 2022/06/28 13:13:05 Benzinga
Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) announced topline results from the Phase 3 RELEASE MSS1 trial of nabiximols oromucosal spray on clinical measures of spasticity in multiple sclerosis. The trial did not meet the primary endpoint of change in Lower Limb Muscle Tone-6 (LLMT-6) between baseline and Day 21. Nabiximols oromucosal spray is a … Full story available on Benzinga.com
Jazz cannabis spray for multiple sclerosis fails phase 3 trial 2022/06/28 12:14:49 Seeking Alpha
Jazz Pharmaceuticals (JAZZ) said its cannabis-based nabiximols oromucosal spray (JZP378) failed to meet the main goal of a late-stage study in patients with multiple…
What SVB Says On Axsome''s Strategy Review On Sunosi For Sleeping Disorder 2022/06/29 19:22:57 Benzinga
Axsome Therapeutics Inc (NASDAQ: AXSM ) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA). SVB Leerink says its view on Sunosi has not changed. Jazz Pharmaceuticals Plc (NASDAQ: JAZZ ) struggled to differentiate Sunosi in a generic market, and SVB remains skeptical that Axsome will be able to do much better. Related: Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its … Full story available on Benzinga.com
IBD 50 Stocks To Watch: This Pharma Stock Rides Health Care Wave 2022/06/29 19:11:15 Investor''s Business Daily
Jazz Pharmaceuticals stands out in the IBD 50 as it rides the wave of the health care sector on concerns of a looming recession.
Jazz Pharma''s Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity 2022/06/28 13:13:05 Benzinga
Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) announced topline results from the Phase 3 RELEASE MSS1 trial of nabiximols oromucosal spray on clinical measures of spasticity in multiple sclerosis. The trial did not meet the primary endpoint of change in Lower Limb Muscle Tone-6 (LLMT-6) between baseline and Day 21. Nabiximols oromucosal spray is a … Full story available on Benzinga.com
Jazz cannabis spray for multiple sclerosis fails phase 3 trial 2022/06/28 12:14:49 Seeking Alpha
Jazz Pharmaceuticals (JAZZ) said its cannabis-based nabiximols oromucosal spray (JZP378) failed to meet the main goal of a late-stage study in patients with multiple…
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity 2022/06/28 11:33:00 Finanz Nachrichten
Nabiximols oromucosal spray continues to be evaluated in ongoing clinical trials in multiple sclerosis spasticity DUBLIN, June 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) toda…